Structure-based design of 2-aminopyridine oxazolidinones as potent and selective tankyrase inhibitors

ACS Medicinal Chemistry Letters

Volumn 4, Issue 12, 2013, Pages 1218-1223

  Huang, Hongbing ^a   Guzman Perez, Angel ^a   Acquaviva, Lisa ^a   Berry, Virginia ^a   Bregman, Howard ^a   Dovey, Jennifer ^a   Gunaydin, Hakan ^a   Huang, Xin ^a   Huang, Liyue ^a   Saffran, Doug ^a   Serafino, Randy ^a   Schneider, Steve ^a   Wilson, Cindy ^a   Dimauro, Erin F ^a  

^a AMGEN INC   (United States)

Author keywords

2 aminopyridine oxazolidinone; cancer; PARP; tankyrase inhibitor; Wnt pathway

Indexed keywords

2 AMINOPYRIDINE OXAZOLIDINONE; 5,5 DIMETHYL 1,3 CYCLOHEXANEDIONE; ENZYME INHIBITOR; NICOTINAMIDE; OXAZOLIDINONE DERIVATIVE; TANKYRASE INHIBITOR; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; AREA UNDER THE CURVE; ARTICLE; CELL PROLIFERATION; COLON CANCER; CONTROLLED STUDY; DRUG BINDING; DRUG BLOOD LEVEL; DRUG DESIGN; DRUG ELIMINATION; DRUG HALF LIFE; DRUG POTENCY; DRUG SCREENING; DRUG SELECTIVITY; DRUG STRUCTURE; DRUG SYNTHESIS; HIGH THROUGHPUT SCREENING; HUMAN; HUMAN CELL; IC 50; MALE; MOUSE; NONHUMAN; PHARMACODYNAMICS; PRIORITY JOURNAL; RAT; TIME TO MAXIMUM PLASMA CONCENTRATION; TUMOR GROWTH; TUMOR XENOGRAFT; WNT SIGNALING PATHWAY;

EID: 84890495266     PISSN: None     EISSN: 19485875     Source Type: Journal    
DOI: 10.1021/ml4003315     Document Type: Article

References (25)

1. Gordon, M. D.; Nusse, R. Wnt signaling: Multiple pathways, multiple receptors, and multiple transcription factors J. Biol. Chem. 2006, 281, 22429-22433
2. Kimelman, D.; Xu, W. beta-Catenin destruction complex: Insights and questions from a structural perspective Oncogene 2006, 25, 7482-7491
3. Yochum, G. S.; Sherrick, C. M.; Macpartlin, M.; Goodman, R. H. A beta-catenin/TCF-coordinated chromatin loop at MYC integrates 5′ and 3′ Wnt responsive enhancers Proc. Natl. Acad. Sci. U.S.A. 2010, 107, 145-150
4. Mirando, A. J.; Maruyama, T.; Fu, J.; Yu, H. M.; Hsu, W. beta-Catenin/cyclin D1 mediated development of suture mesenchyme in calvarial morphogenesis BMC Dev. Biol. 2010, 10, 116
5. Korinek, V.; Barker, N.; Morin, P. J.; van Wichen, D.; de Weger, R.; Kinzler, K. W.; Vogelstein, B.; Clevers, H. Constitutive transcriptional activation by a beta-catenin-Tcf complex in APC-/- colon carcinoma Science 1997, 275, 1784-1787
6. Powell, S. M.; Zilz, N.; Beazer-Barclay, Y.; Bryan, T. M.; Hamilton, S. R.; Thibodeau, S. N.; Vogelstein, B.; Kinzler, K. W. APC mutations occur early during colorectal tumorigenesis Nature 1992, 359, 235-237
7. Tetsu, O.; McCormick, F. Beta-catenin regulates expression of cyclin D1 in colon carcinoma cells Nature 1999, 398, 422-426
8. van de Wetering, M.; Sancho, E.; Verweij, C.; de Lau, W.; Oving, I.; Hurlstone, A.; van der Horn, K.; Batlle, E.; Coudreuse, D.; Haramis, A. P.; Tjon-Pon-Fong, M.; Moerer, P.; van den Born, M.; Soete, G.; Pals, S.; Eilers, M.; Medema, R.; Clevers, H. The beta-catenin/TCF-4 complex imposes a crypt progenitor phenotype on colorectal cancer cells Cell 2002, 111, 241-250
9. Huang, H.; Acquaviva, L.; Berry, V.; Bregman, H.; Chakka, N.; O'Connor, A.; Dimauro, E. F.; Dovey, J.; Epstein, O.; Grubinska, B.; Goldstein, J.; Gunaydin, H.; Hua, Z.; Huang, X.; Huang, L.; Human, J.; Long, A.; Newcomb, J.; Patel, V. F.; Saffran, D.; Serafino, R.; Schneider, S.; Strathdee, C.; Tang, J.; Turci, S.; White, R.; Yu, V.; Zhao, H.; Wilson, C.; Martin, M. W. Structure-based design of potent and selective CK1γ inhibitors ACS Med. Chem. Lett. 2012, 3, 1059-1064
10. Hua, Z.; Huang, X.; Bregman, H.; Chakka, N.; Dimauro, E. F.; Doherty, E. M.; Goldstein, J.; Gunaydin, H.; Huang, H.; Mercede, S.; Newcomb, J.; Patel, V. F.; Turci, S. M.; Yan, J.; Wilson, C.; Martin, M. W. 2-Phenylamino-6-cyano-1 H -benzimidazole-based isoform selective casein kinase 1 gamma (CK1gamma) inhibitors Bioorg. Med. Chem. Lett. 2012, 22, 5392-5395
11. Waaler, J.; Machon, O.; Tumova, L.; Dinh, H.; Korinek, V.; Wilson, S. R.; Paulsen, J. E.; Pedersen, N. M.; Eide, T. J.; Machonova, O.; Gradl, D.; Voronkov, A.; von Kries, J. P.; Krauss, S. A novel tankyrase inhibitor decreases canonical Wnt signaling in colon carcinoma cells and reduces tumor growth in conditional APC mutant mice Cancer Res. 2012, 72, 2822-2832
12. Lehtio, L.; Chi, N. W.; Krauss, S. Tankyrases as drug targets FEBS J. 2013, 280, 3576-3593
13. Huang, S. M.; Mishina, Y. M.; Liu, S.; Cheung, A.; Stegmeier, F.; Michaud, G. A.; Charlat, O.; Wiellette, E.; Zhang, Y.; Wiessner, S.; Hild, M.; Shi, X.; Wilson, C. J.; Mickanin, C.; Myer, V.; Fazal, A.; Tomlinson, R.; Serluca, F.; Shao, W.; Cheng, H.; Shultz, M.; Rau, C.; Schirle, M.; Schlegl, J.; Ghidelli, S.; Fawell, S.; Lu, C.; Curtis, D.; Kirschner, M. W.; Lengauer, C.; Finan, P. M.; Tallarico, J. A.; Bouwmeester, T.; Porter, J. A.; Bauer, A.; Cong, F. Tankyrase inhibition stabilizes axin and antagonizes Wnt signalling Nature 2009, 461, 614-620
14. Chen, B.; Dodge, M. E.; Tang, W.; Lu, J.; Ma, Z.; Fan, C. W.; Wei, S.; Hao, W.; Kilgore, J.; Williams, N. S.; Roth, M. G.; Amatruda, J. F.; Chen, C.; Lum, L. Small molecule-mediated disruption of Wnt-dependent signaling in tissue regeneration and cancer Nat. Chem. Biol. 2009, 5, 100-107
15. Karlberg, T.; Markova, N.; Johansson, I.; Hammarstrom, M.; Schutz, P.; Weigelt, J.; Schuler, H. Structural basis for the interaction between tankyrase-2 and a potent Wnt-signaling inhibitor J. Med. Chem. 2010, 53, 5352-5355
16. Narwal, M.; Venkannagari, H.; Lehtio, L. Structural basis of selective inhibition of human tankyrases J. Med. Chem. 2012, 55, 1360-1367
17. Haikarainen, T.; Venkannagari, H.; Narwal, M.; Obaji, E.; Lee, H. W.; Nkizinkiko, Y.; Lehtio, L. Structural basis and selectivity of tankyrase inhibition by a Wnt signaling inhibitor WIKI4 PLoS One 2013, 8, e65404
18. Gunaydin, H.; Gu, Y.; Huang, X. Novel binding mode of a potent and selective tankyrase inhibitor PLoS One 2012, 7, e33740
19. Lund, F. E. Signaling properties of CD38 in the mouse immune system: Enzyme-dependent and -independent roles in immunity Mol. Med. 2006, 12, 328-333
20. Gharehbaghi, K.; Sreenath, A.; Hao, Z.; Paull, K. D.; Szekeres, T.; Cooney, D. A.; Krohn, K.; Jayaram, H. N. Comparison of biochemical parameters of benzamide riboside, a new inhibitor of IMP dehydrogenase, with tiazofurin and selenazofurin Biochem. Pharmacol. 1994, 48, 1413-1419
21. Bregman, H.; Chakka, N.; Guzman-Perez, A.; Gunaydin, H.; Gu, Y.; Huang, X.; Berry, V.; Liu, J.; Teffera, Y.; Huang, L.; Egge, B.; Mullady, E. L.; Schneider, S.; Andrews, P. S.; Mishra, A.; Newcomb, J.; Serafino, R.; Strathdee, C. A.; Turci, S. M.; Wilson, C.; Dimauro, E. F. Discovery of novel, induced-pocket binding oxazolidinones as potent, selective, and orally bioavailable tankyrase inhibitors J. Med. Chem. 2013, 56, 4320-4342
22. Bregman, H.; Gunaydin, H.; Gu, Y.; Schneider, S.; Wilson, C.; DiMauro, E. F.; Huang, X. Discovery of a class of novel tankyrase inhibitors that bind to both the nicotinamide pocket and the induced pocket J. Med. Chem. 2013, 56, 1341-1345
23. Cui, J. J.; Tran-Dube, M.; Shen, H.; Nambu, M.; Kung, P. P.; Pairish, M.; Jia, L.; Meng, J.; Funk, L.; Botrous, I.; McTigue, M.; Grodsky, N.; Ryan, K.; Padrique, E.; Alton, G.; Timofeevski, S.; Yamazaki, S.; Li, Q.; Zou, H.; Christensen, J.; Mroczkowski, B.; Bender, S.; Kania, R. S.; Edwards, M. P. Structure based drug design of crizotinib (PF-02341066), a potent and selective dual inhibitor of mesenchymal-epithelial transition factor (c-MET) kinase and anaplastic lymphoma kinase (ALK) J. Med. Chem. 2011, 54, 6342-6363
24. Human Kinome. http://kinase.com/human/kinome/ (accessed June 2013).
25. Lau, T.; Chan, E.; Callow, M.; Waaler, J.; Boggs, J.; Blake, R. A.; Magnuson, S.; Sambrone, A.; Schutten, M.; Firestein, R.; Machon, O.; Korinek, V.; Choo, E.; Diaz, D.; Merchant, M.; Polakis, P.; Holsworth, D. D.; Krauss, S.; Costa, M. A novel tankyrase small-molecule inhibitor suppresses APC mutation-driven colorectal tumor growth Cancer Res. 2013, 73, 3132-3144